- University of Rochester, Rochester, New York – PhD in Chemistry
- University of Rochester School of Medicine and Dentistry, Rochester, New York – MD
- New York Presbyterian Hospital, Cornell Campus, New York, New York – Residency in Internal Medicine
- Memorial Sloan Kettering Cancer Center, New York, New York – Fellowship in Medical Oncology
Dr. Mark Burkard is the Mary and Rob Gooze Chair in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine. He is the associate director of Genomics and Precision Medicine within the UW Carbone Cancer Center; a co-leader of the University of Wisconsin Carbone Cancer Center Basket Cancer disease-oriented team; the chair of the UW Carbone Cancer Center/WON Precision Medicine Molecular Tumor Board; and the co-chair of the Big Ten Cancer Research Consortium Basket Group. Dr. Burkard is also the director of the UW-Madison Medical Scientist Training Program. He has received three UW Health Patient Experience Physician Champion Awards, a Komen Madison Award for Commitment to Research and Treatment on Breast Cancer, a UW School of Medicine and Public Health Dean’s Teaching Award and a UW Department of Medicine Page-Grossman Professionalism Award. He is a member of the American Society for Clinical Investigation.
Dr. Burkard is a medical oncologist who specializes in the treatment of breast cancer and in precision oncology.
View Dr. Mark Burkard’s publications on NCBI My Bibliography
Dr. Burkard’s research is focused on understanding the drivers of genomic changes in breast cancer, and developing precision treatments. He is also studying how some patients live many years with metastatic breast cancer. His laboratory seeks to advance cancer therapy by identifying person-to-person differences in cancer behavior and using this knowledge to select the best treatment. Ongoing projects seek to customize treatment for people with metastatic cancer in collaboration with colleagues across Wisconsin and to identify which patients will benefit from targeted drugs, chemotherapy and immunotherapies.